Dec 7, 2020 — 3 min read
A recent study published in a peer-reviewed journal, PLOS ONE, has shown clinical efficacy of an AI algorithm, Lunit INSIGHT CXR, for detecting COVID-19 pneumonia on chest radiography compared with formal radiology reports.
By using a South Korean medical AI company Lunit’s AI software for chest x-rays(Lunit INSIGHT CXR), the study was conducted and revalidated by five different major medical institutions including Kyungpook National University Chilgok Hospital from the Daegu province of South Korea. Daegu is the southeastern city in Korea that had the highest number of COVID-19 cases during the rapid initial development of the cases earlier this year.
The study used actual positive cases from 5 Emergency Departments and 1 community treatment center in the region, between February 18 and May 1, 2020, when the spread began in earnest in the city. In total, chest x-rays of 279 patients were included in the diagnostic analysis.
The results showed that the sensitivity and specificity of Lunit INSIGHT CXR recorded 95.6%, and 88.7%, respectively. No significant difference was observed in the AUROC value of the AI algorithm for the detection of COVID-19 with pneumonia compared with the radiology report.
“Considering the previous AI-based studies for COVID-19 showed an average sensitivity of 80%, this study proves the AI algorithm is significantly improving its performance,” said Brandon Suh, CEO of Lunit. “As the second and third wave of this pandemic is still on-going, Lunit INSIGHT CXR can potentially be used more actively in actual clinical practice in triaging and monitoring COVID-19.”
“In pandemic situations such as the COVID-19, wherein medical resources and personnel are limited, the emergency medical system can be burdened considerably,” stated Professor Dong-eon Lee, the corresponding author of the publication, from Kyungpook National University Chilgok Hospital. “To this end, AI that offers fast and reliable examinations can facilitate decisions regarding patient screening and isolation, thereby reducing the workload on medical staff.”
Lunit INSIGHT CXR clinically analyzed more than 6.5 million images in more than 80 countries, and has an accuracy of 97 to 99% in detecting 10 major chest diseases such as lung nodules and pneumothorax. It is CE marked and clinically available in Europe, Middle East, Latin America, South East Asia, Australia, and New Zealand.
Lunit wins Tumor Proliferation Assessment Challenge (TUPAC) 2016
Lunit to unveil data-driven imaging biomarker at RSNA 2016
Lunit to showcase AI-powered products at USCAP 2017
Lunit INSIGHT: The First-ever, Real-time Imaging AI Analytics on the Web
Cognitive biases and augmented intelligence in radiology
Lunit Returns to RSNA with Real-time Imaging Platform, Featuring Cloud-based A
Lunit Unveils “Lunit INSIGHT,” A New Real-time Imaging AI Platform on the Web at RSNA 2017
Lunit INSIGHT: Q&A with Brandon B. Suh, Chief Medical Officer at Lunit
Media Advisory: Lunit at RSNA 2018
Lunit Opens “Lunit INSIGHT for Mammography” for Public Access
Lunit Brings its Newest AI Solution for Mammography to RSNA 2018
Lunit Partners with Fujifilm and Salud Digna to Provide Medical AI Solution in Mexico
Lunit announces new members in its advisory board: Dr. Eliot Siegel, Dr. Linda Moy, and Dr. Khan Siddiqui
Lunit to Present Abstracts on AI-powered Precision Pathology at 2019 AACR Annual Meeting
Lunit to Showcase AI Solution for Breast Cancer at SBI 2019
Lunit to Present Findings on the Predictive Power of AI Biomarker for Lung Cancer Immunotherapy at ASCO 2019
Lunit Receives Korea MFDS Approval for its AI Solution for Breast Cancer, Lunit INSIGHT MMG
Lunit Gets Korea MFDS Approval for its AI Solution for Chest X-ray, Lunit INSIGHT CXR 2
Lunit at RSNA 2019
Lunit Announces its First CE Mark for AI-Powered Chest X-ray Analysis Software, Lunit INSIGHT CXR
Lunit AI software clinically installed in global sites—to be presented at RSNA 2019
AI-assisted Radiologists Can Detect More Breast Cancer with Reduced False-positive Recall
Lunit Releases Its AI Online to Support Healthcare Professionals Manage COVID-19
Lunit to Present Findings on the Predictive Power of AI-based Analysis of Immune Phenotype at ASCO 2020
Lunit INSIGHT MMG, an AI Solution for Breast Cancer Detection, Now CE Certified
AI Solution for COVID-19, Developed by Medical AI Firm Lunit, Now Has Users in More Than 10 Countries
Lunit at ECR 2020: Providing Virtual Exhibition and Online Presentations
Emergent Connect Partners with Lunit to Provide Cloud Based AI Solutions
AI Analysis Can Improve Lung Cancer Detection on Chest Radiographs
AI has Added Value in Insurance Underwriting Process, Recent Pilot Project Between Lunit and Cathay Financial Innovation Lab Reveals
RSNA 2020--Lunit Collaborates with Global Giants in Presenting its AI Solution at Virtual Booths of GE Healthcare, FujiFilm, and Sectra
AI Proves Its Value in Assistance for Emergency Cases-- With Higher Accuracy and Timely Reporting Time of Chest Radiographs
Lunit Expands Collaboration with GE Healthcare to Advance AI Adoption across Healthcare Industry
Recent Studies Reveal High Performance of Lunit AI in Breast Cancer Detection
South Korean Medical AI Provider and PACS Leader Enters Indonesian Market, to Help COVID-19 Screening and Diagnosis
What do the medical journals say about AI-powered mammography?
Research Using Lunit Demo Website
Lunit Presents AI-powered Pathologic Classification of Immune Phenotype that Predicts Response to Immunotherapy at USCAP 2021
What do the medical journals say about AI-powered chest x-ray interpretation?
Join our webinar with Dr. Fredrik Strand
From retrospective to prospective trials of AI in breast cancer screening
Will AI Identify Breast Cancer Better Than Radiologists in Actual Clinical Screening?
Case of the Month | Where Is Breast Cancer?